Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here. Novo Nordisk's new ...

Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy. The drugmaker has filed a total of 12 ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to competitor Eli Lilly’s efforts to bring a more convenient ...

By Deena Beasley (Reuters) -Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their ...

Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the ...

Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.

Two compounding pharmacies in Florida are allegedly offering contaminated copycat versions of semaglutide, the drug found in Ozempic and Wegovy, Novo Nordisk said Thursday.

Novo Nordisk’s next-generation obesity treatment shows promise in early study. The study tested an injectable form of the drug, amycretin. Novo is also developing a pill form.

Novo Nordisk NVO announced that the Flow trial testing semaglutide in patients with type 2 diabetes and chronic kidney disease will be stopped early after an independent committee concluded that ...

Sept 1 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO has agreed to buy Forma Therapeutics in a deal valued at $1.1 billion to expand its blood disorders portfolio, the companies said on Thursday.